Results 21 to 30 of about 18,708 (185)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation

Frontiers in Cardiovascular Medicine, 2022
BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen, Yunlin Chen, Fang Qin, Huaan Du, Chunxia Gan, Bei Zhou, Na Wang, Mingyang Xiao, Zhenhong Ou, Wei Zhao, Ben Cui, Zengzhang Liu, Yuehui Yin   +12 more
doaj   +1 more source

Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism

Pharmaceutical Biology, 2020
Context Ligustrazine and valsartan are commonly used drugs in the treatment of cardiac and cardiovascular disease. Objective The interaction between ligustrazine and valsartan was studied to investigate the effect of ligustrazine on the pharmacokinetics ...
Yang Liu, Jiaqi Zhang, Di Wu, Liran Cui
doaj   +1 more source

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Journal of Cardiovascular Development and Disease, 2022
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya   +8 more
doaj   +1 more source

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene, Sujung Choi, Steven J. Lippmann, Robert J. Mentz, Melissa A. Greiner, N. Chantelle Hardy, Bradley G. Hammill, Nancy Luo, Marc D. Samsky, Paul A. Heidenreich, Warren K. Laskey, Clyde W. Yancy, Pamela N. Peterson, Lesley H. Curtis, Adrian F. Hernandez, Gregg C. Fonarow, Emily C. O'Brien   +16 more
doaj   +1 more source

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
BackgroundSacubitril/valsartan therapy reduced the risks of death and of hospitalization for heart failure (HF). HF and cardiac arrhythmias have shared physiological mechanisems.
Xue-Hui Liu, Xue-Hui Liu, Guan-Ling Wang, Qiang Xu, Qiang Xu, Lei Zhang, Lei Zhang, Hong-Jun Liu, Hong-Jun Liu   +8 more
doaj   +1 more source

Aerosil in Solid-state Buccal Film for Improved and Sustained Delivery of Valsartan: Molecular Docking Studies [PDF]

Chemical and Biochemical Engineering Quarterly, 2023
To overcome low oral bioavailability and short biological half-life, improved and sustained buccal delivery of valsartan has been proposed. Valsartan film with colloidal silicon dioxide has been prepared using HPMC as mucoadhesive polymer matrix by ...
R. Swain, S. Nandi, P. Bardhan, S. S. Swain, S. Mohapatra, S. Mallick   +5 more
doaj   +1 more source

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

Journal of the American Heart Association, EarlyView., 2021
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes, Claudia Camaioni, João B. Augusto, Kristopher Knott, Ellie Quinn, Gabriella Captur, Andreas Seraphim, George Joy, Petros Syrris, Perry M. Elliott, Saidi Mohiddin, Peter Kellman, Hui Xue, Luis R. Lopes, James C. Moon   +14 more
wiley   +1 more source

Endothelial function of vessels in patients with chronic kidney disease combined with subclinical hypothyroidism under the influence of combined antihypertensive therapy.

Medičnì Perspektivi, 2018
The aim of the study: to evaluate the endothelial function of the vessels under the influence of combined antihypertensive therapy (valsartan 160 mg / amlodipine 5 mg vs valsartan 160 mg / hydrochlorothiazide 12,5 mg) in patients with CKD and subclinical
I. P. Garmish
doaj   +1 more source

Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation

International Journal of Cardiology: Heart & Vasculature, 2019
Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard, Antoine Da Costa, Romain Pierrard, Cécile Roméyer-Bouchard, Jean Baptiste Guichard, Karl Isaaz   +5 more
doaj   +1 more source

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Рациональная фармакотерапия в кардиологии, 2023
Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with ...
A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev   +4 more
doaj   +1 more source